Home > > Global Newborn Screening Market Report
The Newborn Screening market was valued at $850.5 Million in 2022, and is projected to reach $1,856.1 Million by 2032 growing at a CAGR of 8.17% from 2023 to 2032.The newborn screening market is driven by several factors such as the increasing incidence of genetic disorders, growing awareness about newborn screening, and the availability of advanced screening technologies. Additionally, the increasing government support for newborn screening programs and the growing investment in research and development for newborn screening are also driving the market growth. There are several opportunities in the newborn screening market, including the development of new screening technologies, expansion of screening programs to developing countries, and the integration of newborn screening with electronic health records. One of the major trends in the newborn screening market is the increasing use of tandem mass spectrometry as the primary screening technology. This technology offers several advantages over traditional screening methods, including the ability to screen for a larger number of disorders at once and the ability to detect rare disorders. Some of the top companies in the newborn screening market include PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, and Siemens Healthineers. These companies have been actively involved in the development and commercialization of advanced newborn screening technologies and have a strong presence in the global market. For example, PerkinElmer, Inc. has developed the Tandem Mass Spectrometry (MS/MS) Newborn Screening System, which is used for the screening of newborns for a wide range of genetic disorders. Similarly, Bio-Rad Laboratories, Inc. has developed the Bio-Rad DBS System, which is a dried blood spot (DBS) screening system used for newborn screening.